输尿管远端切除术治疗上尿路尿路上皮癌的围手术期与肿瘤学结局:欧洲泌尿外科学会指南专家组的多个中心研究
该回顾性多中心研究纳入2010至2023年间450例接受输尿管远端切除术加膀胱袖状切除的非转移性输尿管远端UTUC患者,评估肿瘤学结局并识别同侧上尿路复发(iUTR)的术前预测因素。5年iUTR无生存率为82%,iUTR发生率16%,术前双J管置入、肿瘤大小和内镜下膀胱袖状处理是iUTR的独立预测因素。
要点
- 输尿管远端切除术围手术期并发症少,90天内仅7%为高级别并发症。
- 低危与高危组在膀胱内无复发生存、iUTR无生存、肿瘤特异生存和总生存上无显著差异。
- 避免术前置管和内镜下膀胱袖状处理可能降低iUTR风险。
核心结论
- 输尿管远端切除术提供良好的围手术期和长期肿瘤学结局,也可适用于选择性的高危病例。
- iUTR并不少见,需延长上尿路随访。
- 避免术前置管和内镜下膀胱袖状处理可能降低iUTR风险。
研究设计与样本
- 回顾性多中心研究,纳入2010至2023年间450例接受输尿管远端切除术加膀胱袖状切除的非转移性输尿管远端UTUC患者。
- 主要终点为iUTR无生存期,次要终点包括膀胱内无复发生存期、无复发生存期、肿瘤特异生存期、总生存期和围手术期结局。
- 采用Kaplan-Meier曲线和多变量Cox回归分析。
主要发现
- 5年iUTR无生存率为82%,膀胱内无复发生存率为49%,无复发生存率为81%,肿瘤特异生存率为89%,总生存率为72%。
- 低危与高危组在膀胱内无复发生存、iUTR无生存、肿瘤特异生存和总生存上无显著差异。
- iUTR发生于16%的患者,其中四分之一在5年后出现。
- 10%的患者接受了挽救性根治性肾输尿管切除术。
- 术前双J管置入(HR 2.85,95%CI 1.11-7.30)、肿瘤大小(HR 1.04,95%CI 1.01-1.07)和内镜下膀胱袖状处理(HR 9.73,95%CI 1.66-56.89)是iUTR的独立预测因素。
关键数值与推荐
- iUTR的独立预测因素包括术前双J管置入(HR 2.85,95%CI 1.11-7.30)、肿瘤大小(HR 1.04,95%CI 1.01-1.07)和内镜下膀胱袖状处理(HR 9.73,95%CI 1.66-56.89)。
临床怎么用
- 输尿管远端切除术可作为低危UTUC的保肾选择,也可考虑用于选择性高危病例。
- 术后需长期随访上尿路以监测iUTR,尤其对于存在术前置管、较大肿瘤或内镜下膀胱袖状处理的患者。
- 避免不必要的术前双J管置入和内镜下膀胱袖状处理可能降低iUTR风险。
局限性
- 回顾性设计。
- 缺乏中心化病理复核。
- 手术技术存在变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Distal ureterectomy (DU) is a kidney-sparing option for low-risk upper tract urothelial carcinoma (UTUC) and may be considered for selected high-risk cases. Long-term outcomes and recurrence predictors remain poorly defined. Our aim was to evaluate oncological outcomes of DU and identify preoperative predictors of disease recurrence, with a particular focus on ipsilateral upper tract recurrence (iUTR). METHODS: This retrospective multicentre study included 450 patients with nonmetastatic UTUC in the distal ureter treated with DU and bladder cuff excision between 2010 and 2023. The primary endpoint was iUTR-free survival (iUTRFS). Secondary endpoints were intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), cancer-specific survival (CSS), overall survival (OS), and perioperative outcomes. Survival outcomes were visualised using Kaplan-Meier curves, and multivariable Cox regression analyses were performed. KEY FINDINGS AND LIMITATIONS: The 5-yr survival estimates were 82% for iUTRFS, 49% for IVRFS, 81% for RFS, 89% for CSS, and 72% for OS. IVRFS, iUTRFS, CSS, and OS did not significantly differ between the low-risk and high-risk groups. iUTR occurred in 16% of patients, with one in four of these cases arising after 5 yr. Salvage radical nephroureterectomy was performed in 10% of patients. Preoperative double-J stenting (hazard ratio [HR] 2.85, 95% confidence interval [CI] 1.11-7.30), tumour size (HR 1.04, 95% CI 1.01-1.07) and endoscopic bladder cuff management (HR 9.73, 95% CI 1.66-56.89) were independent predictors of iUTR. Perioperative complications were rare, with only 7% graded as high grade within 90 d. Limitations include the retrospective design, lack of centralised pathology review, and variability in surgical technique. CONCLUSIONS AND CLINICAL IMPLICATIONS: DU provides favourable perioperative and long-term oncological outcomes and may also be appropriate for selected high-risk cases. iUTR is not uncommon, and prolonged upper tract follow-up is essential. Avoidance of preoperative stenting and endoscopic bladder cuff management may reduce the risk of iUTR.
引用
- Soria F, Liedberg F, Stahl E, et al. Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival Free from Ipsilateral UTUC Recurrence. Eur Urol Oncol. 2025. PMID: 41478781. doi:10.1016/j.euo.2025.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。